Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
CNS Pharmaceuticals, Inc. (CNSP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/23/2023 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Bought 27,000 shares
@ $1.2658, valued at
$34.2k
|
|
| 08/18/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
4
| Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Bought 2,750 shares
@ $1.798, valued at
$4.9k
|
|
| 08/15/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 08/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
4
| Cockroft Bettina M. (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 8,300 options to buy
@ $1.67, valued at
$13.9k
|
|
| 05/09/2023 |
3
| Cockroft Bettina M. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc. |
| 05/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/01/2023 |
4
| Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Exercised 1,250 restricted stock units
@ $0 |
|
| 05/01/2023 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Exercised 521 restricted stock units
@ $0 |
|
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/31/2023 |
4
| Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 16,467 restricted stock units
@ $0 |
|
| 03/31/2023 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 6,067 restricted stock units
@ $0 |
|
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in CNS Pharmaceuticals, Inc. |
| 01/04/2023 |
4
| Charles Faith L. (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 3,500 options to buy
@ $2.4, valued at
$8.4k
|
|
| 01/04/2023 |
3
| Charles Faith L. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc. |
|
|
|